http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
라이브 스트리밍 커머스 앵커 속성이 지각된 가치와 구매 의도에 미치는 영향: 중국의 농산물 시장을 중심으로
( Panting Song ),( Jingyan Ma ),강태원 ( Taewon Kang ) 한국유통경영학회 2021 유통경영학회지 Vol.24 No.6
Purpose: Due to the impact of the COVID-19, the sales of agricultural specialties have been hampered, and live streaming commerce has developed in tandem to provide a channel for the sales of agricultural s pecialties. With the impetus of government policy and market, live streaming + e-commerce has become a new model for the sales of agricultural specialties. This study explores the influence of anchor attributes on the perceived value and purchase intention of agricultural specialties in the live-streaming commerce environment and tries to propose the development of live-streaming commerce of agricultural specialties under the epidemic. Research design, data, and methodology: This study conducted a questionnaire survey of consumers who had purchased agricultural products through live streaming e-commerce. Finally, the survey results of 719 consumers were analyzed using SPSS23.0 and AMOS23.0 on reliability and validity analysis, correlation analysis, path analysis, and mediating analysis. Results: The results of this study show that - first, the professionalism of the anchor has a positive effect on purchase intention and an insignificant effect on the emotional value and perceived risk. Second, the interactivity, entertainment, and trustworthiness of anchors have insignificant positive effects on purchase intention. Third, the mediating effect of perceived emotional value and perceived risk between anchor attributes and purchase intention is significant. Perceived value partially mediates between anchor’s professionalism and purchase intention, while it fully mediates between anchor’s interactivity, entertainment, trustworthiness, and purchase intention. Implications: To better attract consumers to buy agricultural products through live streaming commerce, e-commerce companies should commit to building professional live streaming teams, training anchors, improving their professionalism, and optimizing live streaming content in a consumer-oriented manner. Platforms and relevant departments should also raise the market access threshold, strengthen market supervision, and investigate and deal with behaviors that harm consumers’ legitimate rights and interests.
Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse
Xinyu Wan,Xiaomin Yang,Fan Yang,Tianyi Wang,Lixia Ding,Lili Song,Yan Miao,Xiang Wang,Yani Ma,Chengjuan Luo,Jingyan Tang,Longjun Gu,Jing Chen,Yanjing Tang,Jun Lu,Benshang Li 대한암학회 2022 Cancer Research and Treatment Vol.54 No.3
PurposeAnti-CD19 chimeric antigen receptor T-cell immunotherapy (19CAR-T) has achieved impressive clinical results in adult and pediatric relapsed/refractory (r/r) B-lineage acute lymphoblastic leukemia (B-ALL). However, the application and effect of CAR-T therapy in B-ALL patients with extramedullary relapse are rarely issued even disqualified in some clinical trials. Here, we examined the efficacy of 19CAR-T in patients with both bone marrow and extramedullary involvement.Materials and MethodsCAR-T cells were generated by transfection of primary human T lymphocytes with a lentiviral vector expressing anti-CD19 single chain antibody fragments (scFvs) with the cytoplasmic domains of 4-1BB and CD3ζ, and used to infuse patients diagnosed as having r/r B-ALL with extramedullary origination. Clinical responses were evaluated by the use of bone marrow aspiration, imaging, and flow cytometry. ResultsEight patients received 19CAR-T infusion and all attained complete remission (CR). Only one patient was bridged to hematopoietic stem cell transplantation (HSCT). Although three patients relapsed after infusion, they received 19/22CAR-T infusion sequentially and attained a second remission. To date, five patients are in continuous CR and all eight patients are still alive. The mean follow-up time was 21.9 months, while the 24-month estimated event-free survival is 51.4%. Conclusion19CAR-T therapy can lead to clinical remission for extramedullary relapsed pediatric B-ALL patients. However, the problem of CD19+ relapses after CAR-T remained to be solved. For patients relapsing after CAR-T, a second CAR-T therapy creates another opportunity for remission for subsequent HSCT.